Would an unfavorable molecular subtype cause you to proceed with ALNDx after a positive SLNBx?  

In a patient with a positive SLNBx, would triple negative or Her2+ status affect your decision on whether or not to proceed with a full ALNDx?



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
Here is our data on patients underrepresented in Z...
Sign in or Register to read more